Gulf War Digestive Health Study

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Department of Veterans Affairs Identifier:
First received: May 16, 2008
Last updated: August 29, 2013
Last verified: August 2013

The purposes of this study are to estimate the burden of disease due to chronic gastrointestinal illness in PG veterans, to evaluate whether SBBO is associated with chronic diarrhea in PG veterans, and to determine whether eradication of SBBO reduces symptoms of chronic diarrhea, abdominal pain and bloating in PG veterans.

Condition Intervention
Irritable Bowel Syndrome
Small Intestinal Bacterial Overgrowth
Drug: Placebo
Drug: Rifaximin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Diarrhea-Predominant Irritable Bowel Syndrome in Persian Gulf Veterans

Resource links provided by NLM:

Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • Improvement in IBS Global Improvement Scale. [ Time Frame: once a month for the 6 months following completion of medication ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in Symptom Severity [ Time Frame: 6 months after medication regimen is completed ] [ Designated as safety issue: No ]
  • Change in IBS-QOL Questionnaire [ Time Frame: 1 week after starting the medication, 2 weeks after starting the medication, 1 month after finishing medication, 6 months after finishing medication ] [ Designated as safety issue: No ]
  • Change in LBT [ Time Frame: 6 months after completion of medication ] [ Designated as safety issue: No ]

Enrollment: 140
Study Start Date: October 2007
Estimated Study Completion Date: December 2013
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Arm 1
These patients do not have IBS. They may be deployed or non-deployed veterans.
Active Comparator: Arm 2
These patients have IBS and are receiving the rifaximin.
Drug: Rifaximin
550 mg orally two times per day for 14 days
Placebo Comparator: Arm 3
These patients have IBS and are receiving the placebo.
Drug: Placebo
orally two times per day for 14 days

  Show Detailed Description


Ages Eligible for Study:   35 Years to 72 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women age 32-75 years
  • Rome III criteria for diarrhea-predominant IBS
  • Symptom onset after an apparent episode of acute gastroenteritis
  • Symptoms of > 3 months duration
  • Normal endoscopic appearance of the colonic mucosa
  • Negative markers for celiac disease and inflammatory bowel disease.
  • Normal thyroid function and serum calcium levels.
  • Must have served in the military or reserves during the time of Operation Desert Storm (August 1990 to May 1991)

Exclusion Criteria:

  • Clinically significant cardiac, pulmonary, hepatic or renal dysfunction
  • History of/or presence of systemic malignancy
  • Current evidence of any gastrointestinal disorder such as celiac disease or inflammatory bowel disease (i.e. Crohns disease or ulcerative colitis)
  • Current effects of drug or alcohol abuse
  • Investigator perception of patients inability to comply with study protocol
  • Unstable psychiatric disease
  • Recent change in gastrointestinal medications
  • Subjects with a positive pregnancy test
  • Subject is currently participating in another research protocol that could interfere or influence the outcome measures of the present study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00680836

United States, Utah
Division of Epidemiology
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
Principal Investigator: Ashok K Tuteja, MD MPH Division of Epidemiology
  More Information

No publications provided

Responsible Party: Department of Veterans Affairs Identifier: NCT00680836     History of Changes
Other Study ID Numbers: GWRA-014-05F
Study First Received: May 16, 2008
Last Updated: August 29, 2013
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
Irritable Bowel Syndrome
Gulf War

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Gastrointestinal Agents processed this record on August 27, 2014